Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?
BACKGROUND
The aim of the study was to assess the effectiveness of peptide receptor radionuclide therapy (PRRT) in patients with non-functioning neuroendocrine pancreatic tumours (NFPNTs) and to compare survival rates in patients with NFPNTs and in patients with other neuroendocrine tumours (NETs) treated using radiolabelled somatostatin analogue in our Department. We would like to analyze factors potentially determining the effectiveness of the therapy and also to assess the myelo- and nephrotoxicity.


METHODS
Fourteen patients with disseminated disease and/or inoperable NFPNT were qualified to PRRT based on positive SRS (somatostatin receptor scintigraphy). There were 5 men and 9 women, with Karnofsky's index>70%.


RESULTS
In the whole group of patients, partial response was observed in 21.4%, stabilization of the disease in 42.9%, and progression of the disease in 35.7% of patients. Mean observation time was 19±13 months, mean time to progression was 12±9 months, and mean time to death was 16±9 months. Six patients died--four of them due to progression of the disease, two due to myocardial infarction. After PRRT we did not observe clinically significant haemotoxicity and/or nephrotoxicity.


CONCLUSIONS
1. Peptide receptor radionuclide therapy may be a safe and effective treatment option in patients with NFPNTs, leading to stabilization or regression of the disease in the majority of patients. 2. There is no statistically significant difference in survival rate between patients with NFPNTs and NETs of other localization treated with PRRT.
Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland.
Anna
A
Sowa-Staszczak
Dorota
D
Pach
Agnieszka
A
Stefańska
Monika
M
Tomaszuk
Wioletta
W
Lenda-Tracz
Renata
R
Mikołajczak
Dariusz
D
Pawlak
Robert
R
Chrzan
Aleksandra
A
Gilis-Januszewska
Elwira
E
Przybylik-Mazurek
Alicja
A
Hubalewska-Dydejczyk
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D018000:Receptors, Peptide / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000378:metabolism*; D015996:Survival Rate; D016896:Treatment Outcome
C539274:90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-; D009942:Organometallic Compounds; D018000:Receptors, Peptide; D017481:Receptors, Somatostatin; C447941:lutetium Lu 177 dotatate; D015282:Octreotide